22 December 2023
22 December 2023
As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital.
The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.
The development is based on findings from the Phase I/II trial of BNT323/DB-1303 in advanced endometrial cancer patients.
The deal is worth up to $494m plus royalties and allows Lilly to utilise Fauna’s Convergence artificial intelligence platform.
Lyndra will use the funds to complete a Phase III trial in schizophrenia and schizoaffective disorder for its risperidone candidate.
This signifies the third submission in four months from J&J for the Rybrevant development programme.
Sudo plans to advance two tyrosine kinase 2 (TYK2) candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.
The partnership aims to leverage EVQLV's advanced technology to generate therapeutic antibody designs against multiple targets selected by Ono.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
A comprehensive outlook for the leading players across the TMT industry, based on the key themes set to transform the industry landscape over the next two years. You will not find a better guide to technology in 2024.
Give your business an edge with our leading industry insights.
